<DOC>
	<DOCNO>NCT01653119</DOCNO>
	<brief_summary>The purpose study explore effect 20mg high load dose rosuvastatin recurrent event patient establish DM admit ACS .</brief_summary>
	<brief_title>Peking Rotterdam Mission Reduce Coronary Artery Disease</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>• Men woman ≥40 year age admit clinical diagnosis ACS . The diagnosis base combination typical ischemic chest complaint objective evidence myocardial ischemia myocardial necrosis demonstrate electrocardiogram ( ECG ) elevate cardiac marker , follow : Typical ischemic chest pain , last 10 minute , within precede 24 hour , AND either ECG change indicative myocardial ischemia within 24 hour onset chest pain ( ECG show persistent nonpersistent STsegment elevation &gt; 1.0 mm two contiguous lead dynamic STsegment depression &gt; 1.0 mm two contiguous lead ) Elevated biomarkers myocardial necrosis within 24 hour onset chest pain ( i.e . CKMB &gt; 1 time upper limit normal local laboratory , TroponinT &gt; 0.1 ng/ml . A diagnosis DM type II prior index ACS Written inform consent • Myocardial ischemia precipitate condition atherosclerotic coronary artery disease ( e.g . arrhythmia , severe anemia , hypoxia , thyrotoxicosis , cocaine , severe valvular disease , hypotension ) . Severelyimpaired leave ventricular function ( ejection fraction &lt; 30 % ) endstage congestive heart failure NYHAclass III IV ( order avoid losttofollowup due nonacute coronary syndrome event ) . Severe chronic kidney disease measure calculated glomerular filtration rate ( CockgroftGault MDRD4 ( Modification Diet Renal Disease ) formula ) &lt; 30 ml/min/1.73m2 , renal dialysis . Coexistent condition associate lifeexpectancy &lt; 12 month , otherwise unlikely appear schedule followup visit . Known serious hypersensitivity reaction HMGCoA reductase inhibitor . Triglyceride ( TG ) level ≥500 mg/dL ( 5.65 mmol/L ) screening , patient high triglyceride level warrant treatment agent may increase risk side effect associate statin drug . Active liver disease hepatic dysfunction , determine alanine aminotransferase ( ALT [ SGPT ] ) &gt; 3 x ULN bilirubin level &gt; 1.5 x ULN screening . Myopathy . Not use effective contraceptive method . Participation investigational drug study le 30 day prior enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Statins</keyword>
	<keyword>High loading dose</keyword>
	<keyword>Recurrent event</keyword>
</DOC>